CEO Carmine Stengone (Pipeline Therapeutics)

Ver­sant spin­out lands $80M to go 'much broad­er' than the old Roche part­ner­ship that birthed it

About three years af­ter split­ting from Ver­sant Ven­tures’ dis­cov­ery group, Pipeline Ther­a­peu­tics has land­ed an $80 mil­lion Se­ries C round to go “much broad­er” than …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.